Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Q2 2026 Earnings Surge as iPhone 17 Sales Drive Record Revenue 
Berkshire Hathaway Meeting Sees Shift as Greg Abel Steps Into Leadership Spotlight 
Middle East Conflict Impacts Australia and New Zealand Businesses 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
Amazon Stock Dips Despite Record Earnings as AI Infrastructure Spending Surges 
Meta Raises 2026 Capex Outlook Amid AI Spending Surge, Shares Drop After Earnings 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Ford Q1 Earnings Beat Expectations, Stock Surges on Strong Guidance 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Coles Group Q3 Sales Rise Driven by Supermarkets and E-Commerce Growth 
Alphabet Earnings Surge on AI Growth, Cloud Revenue, and Strong Search Performance 
CARLSBAD, Calif., May 02, 2018 -- GenMark Diagnostics, Inc. (NASDAQ:GNMK) a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that President and Chief Executive Officer, Hany Massarany, will present at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV.
Mr. Massarany is scheduled to present on Wednesday, May 16 at 9:20 a.m. Pacific Time. Interested parties may access a live and archived webcast of the event at ir.genmarkdx.com.
ABOUT GENMARK DIAGNOSTICS
GenMark Diagnostics (NASDAQ:GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and reduce the total cost-of-care. Utilizing GenMark's proprietary eSensor® detection technology, GenMark's eSensor XT-8® and ePlex® systems are designed to support a broad range of molecular diagnostic tests with compact, easy-to-use workstations and self-contained, disposable test cartridges. GenMark’s ePlex: The True Sample-to-Answer Solution™ is designed to optimize laboratory efficiency and address a broad range of infectious disease testing needs, including respiratory, bloodstream, and gastrointestinal infections. For more information, visit www.genmarkdx.com.
Investor Relations Contact
Lynn Pieper Lewis or Leigh Salvo
(415) 937-5404
[email protected]
